19.2 Plan Nutritional Strategies to Impact Musculoskeletal and Integumentary Wellness

Potassium channel blockers are game-changers in treating dangerous heart rhythms. These drugs slow down the heart's electrical signals, giving cardiac cells more time to recover and preventing life-threatening arrhythmias.

While effective, these medications come with risks. Nurses must closely monitor patients for side effects like QT prolongation and watch for signs of trouble. Patient education is key to ensure proper use and prompt reporting of any issues.

Class III Antiarrhythmic Drugs: Potassium Channel Blockers

Features of potassium channel blockers

Top images from around the web for Features of potassium channel blockers

• 

  19.2 Cardiac Muscle and Electrical Activity – Anatomy and Physiology View original

  Is this image relevant?

• 

  Cardiac Muscle and Electrical Activity | Anatomy and Physiology II View original

  Is this image relevant?

• 

  Cardiac Physiology | Anatomy and Physiology II View original

  Is this image relevant?

• 

  19.2 Cardiac Muscle and Electrical Activity – Anatomy and Physiology View original

  Is this image relevant?

• 

  Cardiac Muscle and Electrical Activity | Anatomy and Physiology II View original

  Is this image relevant?

1 of 3

Top images from around the web for Features of potassium channel blockers

• 

  19.2 Cardiac Muscle and Electrical Activity – Anatomy and Physiology View original

  Is this image relevant?

• 

  Cardiac Muscle and Electrical Activity | Anatomy and Physiology II View original

  Is this image relevant?

• 

  Cardiac Physiology | Anatomy and Physiology II View original

  Is this image relevant?

• 

  19.2 Cardiac Muscle and Electrical Activity – Anatomy and Physiology View original

  Is this image relevant?

• 

  Cardiac Muscle and Electrical Activity | Anatomy and Physiology II View original

  Is this image relevant?

1 of 3

• Prolong the action potential duration and effective refractory period in cardiac cells
  • Increase the time for cardiac cells to recover preventing premature contractions (early afterdepolarizations)
• Primarily used to treat ventricular arrhythmias
  • Treat life-threatening rhythms such as ventricular tachycardia and ventricular fibrillation
• Examples of Class III antiarrhythmic drugs
  • Amiodarone, dronedarone (Multaq), sotalol (Betapace), dofetilide (Tikosyn), ibutilide (Corvert)

Mechanism of Class III antiarrhythmics

• Block potassium channels, particularly the rapid component of the delayed rectifier potassium current ($I_{Kr}$)
  • Blocking $I_{Kr}$ slows repolarization leading to prolongation of action potential duration and effective refractory period
• Indications
  • Prevent and treat life-threatening ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation)
  • Maintain sinus rhythm in patients with atrial fibrillation or flutter
• Major side effects
  • QT interval prolongation and risk of torsades de pointes (polymorphic ventricular tachycardia)
  • Bradycardia and heart block due to prolonged repolarization
  • Pulmonary toxicity with amiodarone (pneumonitis, pulmonary fibrosis)
  • Thyroid dysfunction with amiodarone (hypo- or hyperthyroidism)
  • Gastrointestinal disturbances (nausea, vomiting, diarrhea)
  • Visual disturbances with amiodarone (halos, blurred vision, photophobia)

Cardiac Electrophysiology and Antiarrhythmic Drug Action

• Action potential: The electrical signal that triggers contraction in cardiac cells
• Repolarization: The phase of the action potential where the cell returns to its resting state
• Ion channels: Specialized proteins in cell membranes that control the flow of ions, crucial for generating action potentials
• Arrhythmia: Abnormal heart rhythm caused by disruptions in the heart's electrical system
• Antiarrhythmic drugs: Medications designed to correct arrhythmias by modifying cardiac electrophysiology

Nursing considerations for channel blockers

• Assess baseline and ongoing ECG for QT interval prolongation
  • Monitor for QTc >500ms which increases risk of torsades de pointes
• Monitor electrolyte levels, particularly potassium and magnesium
  • Correct any electrolyte imbalances before and during therapy to reduce proarrhythmic risk
• Observe for signs and symptoms of proarrhythmia (torsades de pointes)
  • Watch for palpitations, syncope, or sudden cardiac arrest
• Administer medications as prescribed and educate patients on the importance of adherence
  • Missed doses can lead to recurrence of arrhythmia
• Be aware of drug interactions that may increase the risk of adverse effects
  • Avoid concomitant use of other QT-prolonging agents (certain antibiotics, antipsychotics, antiemetics)
• Regularly assess and monitor liver, thyroid, and pulmonary function with amiodarone use
  • Obtain baseline tests and monitor every 6 months

Patient education for antiarrhythmic medications

• Emphasize the importance of taking medications as prescribed and not discontinuing without consulting their healthcare provider
  • Abrupt discontinuation can worsen arrhythmia
• Instruct patients to report any signs or symptoms of adverse effects
  • Advise to alert provider for palpitations, dizziness, fainting, shortness of breath, vision changes, or gastrointestinal disturbances
• Advise patients to inform all healthcare providers about their antiarrhythmic medication use
  • Crucial to avoid drug interactions and monitor for side effects
• Encourage regular follow-up appointments for monitoring of therapy effectiveness and adverse effects
  • Typically every 3-6 months or more frequently if issues arise
• Discuss the importance of maintaining a heart-healthy lifestyle
  • Engage in regular exercise, eat a healthy diet, manage stress, and stop smoking
• Educate patients on the potential for drug interactions and the need to consult their healthcare provider before starting any new medications, supplements, or herbal products
  • Many compounds can affect metabolism of antiarrhythmics or exacerbate side effects